SPC24 promotes osteosarcoma progression by increasing EGFR/MAPK signaling.

Area of Science:

• Oncology
• Molecular Biology
• Cell Biology

Background:

• Osteosarcoma is a primary bone cancer with poor prognosis.
• The spindle assembly checkpoint protein SPC24 is implicated in cell division.
• The role of SPC24 in cancer progression, particularly osteosarcoma, remains unclear.

Purpose of the Study:

• To investigate the role of SPC24 in osteosarcoma progression.
• To determine the molecular mechanisms by which SPC24 influences osteosarcoma cell behavior.
• To evaluate SPC24 as a potential therapeutic target in osteosarcoma.

Main Methods:

• SPC24 was knocked down in osteosarcoma cell lines (143B, U2OS) using siRNA.
• Cell growth, survival, and invasiveness assays were performed.
• Expression levels of EGFR, Ras, phospho-ERK, and E-cadherin were analyzed.
• Xenograft models in nude mice were used to assess tumor growth in vivo.
• Human osteosarcoma tissue samples were analyzed for SPC24 and related protein expression.

Main Results:

• SPC24 knockdown significantly decreased osteosarcoma cell growth, survival, and invasiveness.
• Knockdown cells showed reduced levels of EGFR, Ras, and phospho-ERK, and increased E-cadherin.
• These molecular changes suggest inhibition of EGFR/Ras/ERK signaling and epithelial-to-mesenchymal transition (EMT).
• Xenograft studies confirmed reduced tumor growth with SPC24 knockdown, accompanied by decreased EGFR/phospho-ERK and increased E-cadherin.
• Human osteosarcoma tissues exhibited high SPC24 and phospho-ERK levels, and low E-cadherin levels.

Conclusions:

• SPC24 promotes osteosarcoma progression.
• SPC24 enhances osteosarcoma progression by upregulating EGFR/Ras/ERK signaling.
• SPC24 may be a potential therapeutic target for inhibiting osteosarcoma growth and metastasis.